Richard M. Sherry, M.D.

Richard M. Sherry, M.D.
Associate Research Physician
Surgery Branch

Team Member of:

Steven A. Rosenberg, M.D., Ph.D.

Dr. Sherry is a senior member of the Surgery Branch immunotherapy team and also serves as a consultant surgeon at the NCI Center for Cancer Research and the NIH Clinical Center. His work is focused on the design and conduct of clinical trials that seek to translate the principles of tumor immunology elucidated in basic science laboratories. These efforts have helped to develop effective immunotherapies for patients with advanced cancer that include Interleukin-2, Ipilimumab, tumor infiltrating lymphocytes (TIL), and chimeric antigen receptor(CAR) T Cells. Dr. Sherry is also involved with the clinical training, education, and professional development of Surgery Branch fellows

Areas of Expertise
1) immunotherapy 2) T cell adoptive therapy 3) genetically-modified peripheral blood lymphocytes 4) melanoma 5) clinical trial design in oncology

Contact Info

Richard M. Sherry, M.D.
Center for Cancer Research
National Cancer Institute
Building 10, Room 2B38
Bethesda, MD 20892
Ph: 240-760-6219
Richard_Sherry@nih.gov
Permalink

Dr. Sherry’s research is directed to the clinical development of effective immunotherapies for patients with common cancers based on the adoptive transfer of autologous TIL and genetically modified lymphocytes. These efforts involve the translation of novel findings and strategies in tumor immunology developed in Surgery Branch laboratories and cell processing facilities and include protocol development, patient accrual, management of patients with advanced cancer, and data analysis. His research goal is to make cellular cancer immunotherapy effective, safe, and practical. 

NIH Scientific Focus Areas:
Clinical Research
View Dr. Sherry's PubMed Summary.

Selected Recent Publications

  1. Complete regression of metastatic cervical cancer after treatment with human papillomavirus-targeted tumor-infiltrating T cells .
    Stevanović S, Draper LM, Langhan MM, Campbell TE, Kwong ML, Wunderlich JR, Dudley ME, Yang JC, Sherry RM, Kammula US, Restifo NP, Rosenberg SA, Hinrichs CS.
    J Clin Oncol. 33(14): 1543-50, 2015. [ Journal Article ]
  2. Tumor-infiltrating lymphocytes genetically engineered with an inducible gene encoding interleukin-12 for the immunotherapy of metastatic melanoma .
    Zhang L, Morgan RA, Beane JD, Zheng Z, Dudley ME, Kassim SH, Nahvi AV, Ngo LT, Sherry RM, Phan GQ, Hughes MS, Kammula US, Feldman SA, Toomey MA, Kerkar SP, Restifo NP, Yang JC, Rosenberg SA.
    Clin Cancer Res. 21(10): 2278-88, 2015. [ Journal Article ]
  3. A pilot trial using lymphocytes genetically engineered with an NY-ESO-1-reactive T-cell receptor: long-term follow-up and correlates with response .
    Robbins PF, Kassim SH, Tran TL, Crystal JS, Morgan RA, Feldman SA, Yang JC, Dudley ME, Wunderlich JR, Sherry RM, Kammula US, Hughes MS, Restifo NP, Raffeld M, Lee CC, Li YF, El-Gamil M, Rosenberg SA.
    Clin Cancer Res. 21(5): 1019-27, 2015. [ Journal Article ]
  4. Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor .
    Kochenderfer JN, Dudley ME, Kassim SH, Somerville RP, Carpenter RO, Stetler-Stevenson M, Yang JC, Phan GQ, Hughes MS, Sherry RM, Raffeld M, Feldman S, Lu L, Li YF, Ngo LT, Goy A, Feldman T, Spaner DE, Wang ML, Chen CC, Kranick SM, Nath A, Nathan DA, Morton KE, Toomey MA, Rosenberg SA.
    J Clin Oncol. 33(6): 540-9, 2015. [ Journal Article ]
  5. Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy.
    Morgan RA, Chinnasamy N, Abate-Daga D, Gros A, Robbins PF, Zheng Z, Dudley ME, Feldman SA, Yang JC, Sherry RM, Phan GQ, Hughes MS, Kammula US, Miller AD, Hessman CJ, Stewart AA, Restifo NP, Quezado MM, Alimchandani M, Rosenberg AZ, Nath A, Wang T, Bielekova B, Wuest SC, Akula N, McMahon FJ, Wilde S, Mosetter B, Schendel DJ, Laurencot CM, Rosenberg SA
    J Immunother. 36(2): 133-51, 2013. [ Journal Article ]

Dr. Sherry is a graduate of Tufts University and the University of Pennsylvania School of Medicine. He trained in surgery at the University of Pennsylvania and the Kaiser Foundation in San Francisco and subsequently completed a fellowship in surgical oncology and immunotherapy at the NCI Surgery Branch.  From 1991 to 1998, Rick held joint appointments as an attending surgeon in surgical oncology at the Georgia Regents Medical Center and the Augusta Veterans Administration Hospital where he rose to the rank of Associate Professor of Surgery.  In 1998, he was recruited to the senior staff of the NCI Surgery Branch. Dr. Sherry is a diplomate of the American Board of Surgery, a Fellow of the American College of Surgeons, and an attending surgeon at the NIH Clinical Center. He is a co-recipient of the Society for Immunotherapy of Cancer Team Science Award and a NIH Clinical Center Directors Award for Strategic Initiatives. 

Research

Dr. Sherry’s research is directed to the clinical development of effective immunotherapies for patients with common cancers based on the adoptive transfer of autologous TIL and genetically modified lymphocytes. These efforts involve the translation of novel findings and strategies in tumor immunology developed in Surgery Branch laboratories and cell processing facilities and include protocol development, patient accrual, management of patients with advanced cancer, and data analysis. His research goal is to make cellular cancer immunotherapy effective, safe, and practical. 

NIH Scientific Focus Areas:
Clinical Research

Publications

View Dr. Sherry's PubMed Summary.

Selected Recent Publications

  1. Complete regression of metastatic cervical cancer after treatment with human papillomavirus-targeted tumor-infiltrating T cells .
    Stevanović S, Draper LM, Langhan MM, Campbell TE, Kwong ML, Wunderlich JR, Dudley ME, Yang JC, Sherry RM, Kammula US, Restifo NP, Rosenberg SA, Hinrichs CS.
    J Clin Oncol. 33(14): 1543-50, 2015. [ Journal Article ]
  2. Tumor-infiltrating lymphocytes genetically engineered with an inducible gene encoding interleukin-12 for the immunotherapy of metastatic melanoma .
    Zhang L, Morgan RA, Beane JD, Zheng Z, Dudley ME, Kassim SH, Nahvi AV, Ngo LT, Sherry RM, Phan GQ, Hughes MS, Kammula US, Feldman SA, Toomey MA, Kerkar SP, Restifo NP, Yang JC, Rosenberg SA.
    Clin Cancer Res. 21(10): 2278-88, 2015. [ Journal Article ]
  3. A pilot trial using lymphocytes genetically engineered with an NY-ESO-1-reactive T-cell receptor: long-term follow-up and correlates with response .
    Robbins PF, Kassim SH, Tran TL, Crystal JS, Morgan RA, Feldman SA, Yang JC, Dudley ME, Wunderlich JR, Sherry RM, Kammula US, Hughes MS, Restifo NP, Raffeld M, Lee CC, Li YF, El-Gamil M, Rosenberg SA.
    Clin Cancer Res. 21(5): 1019-27, 2015. [ Journal Article ]
  4. Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor .
    Kochenderfer JN, Dudley ME, Kassim SH, Somerville RP, Carpenter RO, Stetler-Stevenson M, Yang JC, Phan GQ, Hughes MS, Sherry RM, Raffeld M, Feldman S, Lu L, Li YF, Ngo LT, Goy A, Feldman T, Spaner DE, Wang ML, Chen CC, Kranick SM, Nath A, Nathan DA, Morton KE, Toomey MA, Rosenberg SA.
    J Clin Oncol. 33(6): 540-9, 2015. [ Journal Article ]
  5. Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy.
    Morgan RA, Chinnasamy N, Abate-Daga D, Gros A, Robbins PF, Zheng Z, Dudley ME, Feldman SA, Yang JC, Sherry RM, Phan GQ, Hughes MS, Kammula US, Miller AD, Hessman CJ, Stewart AA, Restifo NP, Quezado MM, Alimchandani M, Rosenberg AZ, Nath A, Wang T, Bielekova B, Wuest SC, Akula N, McMahon FJ, Wilde S, Mosetter B, Schendel DJ, Laurencot CM, Rosenberg SA
    J Immunother. 36(2): 133-51, 2013. [ Journal Article ]

Biography

Dr. Sherry is a graduate of Tufts University and the University of Pennsylvania School of Medicine. He trained in surgery at the University of Pennsylvania and the Kaiser Foundation in San Francisco and subsequently completed a fellowship in surgical oncology and immunotherapy at the NCI Surgery Branch.  From 1991 to 1998, Rick held joint appointments as an attending surgeon in surgical oncology at the Georgia Regents Medical Center and the Augusta Veterans Administration Hospital where he rose to the rank of Associate Professor of Surgery.  In 1998, he was recruited to the senior staff of the NCI Surgery Branch. Dr. Sherry is a diplomate of the American Board of Surgery, a Fellow of the American College of Surgeons, and an attending surgeon at the NIH Clinical Center. He is a co-recipient of the Society for Immunotherapy of Cancer Team Science Award and a NIH Clinical Center Directors Award for Strategic Initiatives.